Tag

Novo Nordisk

All articles tagged with #novo nordisk

business10 hours ago•3 min saved

Novo Nordisk bets $2.1B on next-gen oral biologics with Vivtex

Novo Nordisk plans to invest up to $2.1 billion in Vivtex to advance next-generation oral delivery systems for biologics, leveraging Vivtex’s GI tract screening platform developed in MIT labs. Novo will fund research and later development and commercialization, aiming to expand its lead in oral obesity and diabetes therapies after Wegovy’s pill launch, while Vivtex pursues broad partnership opportunities and potential standalone programs.

via Fierce Biotech|

#biologics #business #novo-nordisk

pharma17 hours ago•2 min saved

Novo Nordisk teams with Langer-founded Vivtex on oral obesity therapies

Novo Nordisk is partnering with Vivtex, a biotech co-founded by MIT’s Robert Langer, to develop oral obesity therapies, expanding the pharmaceutical giant’s push into obesity drugs.

via Endpoints News|

#novo-nordisk #obesity #oral-drugs

business1 day ago•3 min saved

CagriSema lags Zepbound as Novo Nordisk presses toward FDA decision

Novo Nordisk’s obesity drug CagriSema delivered slightly less weight loss than Lilly’s Zepbound in an 84-week phase 3 trial, raising questions about its market potential ahead of a late-2026 FDA decision and a possible 2027 launch. Novo defends the drug’s efficacy and points to additional trials (REDEFINE 11 and a higher-dose study) while analysts warn it may struggle to gain share from Zepbound, signaling potential reliance on future deals to bolster its pipeline.

via CNBC|

#business #cagrisema #novo-nordisk

business1 day ago•2 min saved

Novo Nordisk slashes Wegovy and Ozempic prices to boost affordability

Novo Nordisk will cut Wegovy by 50% and Ozempic by 35% starting January 2027, setting a $675 per-month price for both drugs and for Rybelsus as well, as it faces competition from Lilly’s Mounjaro/Zepbound and other GLP-1 therapies; the company says the cuts aim to lower out-of-pocket costs for patients with high-deductible plans, and direct-to-patient discounts will remain unchanged.

via CBS News|

#business #glp-1 #novo-nordisk

business1 day ago•4 min saved

Drugmaker slashes US price of weight-loss therapy

Novo Nordisk has halved the US price of its weight‑loss drug, a move aimed at broadening access amid strong demand and competition in the GLP‑1 market.

via Financial Times|

#business #novo-nordisk #pharmaceutical-pricing

business1 day ago•3 min saved

Novo Nordisk to cut U.S. GLP-1 drug prices by up to 50% in 2027

Novo Nordisk said U.S. list prices for Wegovy, Ozempic, and Rybelsus will be cut by up to 50% to $675 per month starting Jan. 1, 2027, targeting insured patients with high-deductible plans or co-insurance and potentially lowering out-of-pocket costs; Medicare prices will also drop to $274 per month under the Inflation Reduction Act, aiming to boost access and competition in the GLP-1 market.

via CNBC|

#business #novo-nordisk #ozempic

business2 days ago•2 min saved

CagriSema setback hits Novo Nordisk as trials disappoint

Novo Nordisk’s next‑gen weight‑loss drug CagriSema failed to meet its primary endpoint in a late‑stage trial, delivering 23% average weight loss over 84 weeks versus 25.5% for Eli Lilly’s tirzepatide, prompting a sharp stock drop and renewed investor skepticism. The company plans a higher‑dose study and continues pursuing approval based on earlier data, while analysts noted the result as a setback for its obesity‑drug ambitions.

via The Guardian|

#business #cagrisema #clinical-trial-results

business16 days ago•3 min saved

Novo Nordisk sues rival over unapproved, knock-off weight-loss drugs

Novo Nordisk has filed a US lawsuit to block Hims & Hers from selling weight‑loss pills and injections it says are unapproved and infringe its patents, arguing safety concerns over compounded versions. The move comes as the FDA tightens rules on compounding, and amid broader pressure from expiring patents on Wegovy/Ozempic; Hims & Hers’ stock fell while Novo Nordisk edged higher following the filing.

via BBC|

#business #fda #hims-and-hers

health16 days ago•2 min saved

FDA flags Wegovy ad as misleading, orders corrective actions

The FDA says Novo Nordisk’s Wegovy TV ad makes false or misleading claims, overstating benefits and not adequately presenting risks, and it calls for immediate corrective action that could include halting the ads; the move comes as Novo battles Eli Lilly and copycats in the GLP-1 obesity market, with Wegovy gaining adopters since its January launch.

via CNBC|

#advertising #fda #glp-1

business17 days ago•4 min saved

Novo Nordisk targets Hims with lawsuit over cheap Wegovy copycats

Novo Nordisk filed a lawsuit seeking a permanent ban and damages against Hims & Hers for allegedly selling compounded, patent-infringing versions of Wegovy (semaglutide); Hims paused its obesity-pill copycat after regulatory scrutiny as FDA actions loom, underscoring a broader crackdown on compounded GLP-1 drugs used by as many as 1.5 million Americans amid intense obesity-drug competition.

via CNBC|

#business #compounding #hims-and-hers

business17 days ago•14 min saved

Hims & Hers drops plan to copy Wegovy weight‑loss drug

Hims & Hers has canceled its plan to develop a Wegovy‑style weight‑loss medication, shelving a project to mimic Novo Nordisk’s semaglutide as the company reassesses its drug‑development strategy in the competitive obesity market.

via AP News|

#business #hims-and-hers #novo-nordisk

health18 days ago•2 min saved

Hims & Hers halts compounded Wegovy copy amid federal probe

Hims & Hers will stop selling a cheaper, compounded version of Novo Nordisk’s obesity pill Wegovy after health officials called for an investigation into possible federal-law violations; the platform had offered a $49/month compounded version, while Novo Nordisk’s Wegovy costs $149–$299/month, as FDA and HHS/DOJ actions move to curb unapproved compounded GLP-1 drugs.

via statnews.com|

#compounded-drugs #glp-1 #health

stock-markets18 days ago•129 min saved

Walmart Leads Week as PayPal Slides: Investing.com’s Stocks of the Week

Investing.com highlights a mixed week: Walmart up over 11% to push above $130 and lift its market value past $1 trillion; PayPal down more than 23% after a disappointing earnings report and leadership change; Novo Nordisk down over 21% amid pricing headwinds; Silicon Laboratories surges about 44% as Texas Instruments agrees to acquire it for roughly $7.5 billion; MicroStrategy up about 24% on Friday but the week overall is around -5%; Amazon slides over 5% after a capex-heavy forecast, with Bitcoin price swings anchoring several moves.

via Investing.com|

#microstrategy #novo-nordisk #paypal

business20 days ago•3 min saved

Novo Nordisk to sue over Hims & Hers Wegovy copy

Novo Nordisk said it will take legal and regulatory action against telehealth provider Hims & Hers after it unveiled a cheaper copycat Wegovy. Hims plans an oral semaglutide pill priced at $49 for the first month and $99 thereafter under a 5-month plan, triggering about 7% declines in Novo Nordisk and Eli Lilly shares; Novo argues the product is illegal mass compounding that risks patient safety, while Hims says its copy uses a different formulation. Wegovy’s SNAC absorption technology is a key point of contrast, and Lilly is preparing its own oral GLP-1, orforglipron, pending FDA approval.

via CNBC|

#business #glp-1 #hims-and-hers

business20 days ago•5 min saved

Novo Nordisk fights back as rival offers $49 weight‑loss semaglutide

Novo Nordisk says Hims & Hers’ new $49/month, compounded semaglutide version of Wegovy is illegal mass compounding and unsafe, pledging legal action; the FDA has warned against copycat GLP‑1 drugs. The move intensifies price competition in obesity drugs, with Novo forecasting up to a 13% drop in net sales and shares for Novo Nordisk and Lilly slipping.

via Financial Times|

#business #fda #hims-and-hers